I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 011823-004920US Client Reference No.: PDL0049-20

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450

on Way 2, 2007

Susan

TOWNSHIND and TOWNSEND and CREW LLR

COPY

MAY 1 0 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

J. YUN TSO

Application No.: 09/618,380

Filed: July 18, 2000

For: HUMANIZED ANTIBODIES

AGAINST CD3

Confirmation No.: 9002

Examiner: L. Helms

Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

J. YUN TSO

Application No.: 09/618,380

Page 2

information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please deduct any additional fees from, or credit any overpayment to Deposit Account No. 20-1430.

Respectfully submitted,

Joe Liebeschuetz Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

JOL:sjj

61011069

MAY 1 0 2007

ubstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3

Complete if Known					
09/618,380					
July 18, 2000					
TSO, J. YUN					
1642					
L. Helms					
011823-004920US					
	09/618,380 July 18, 2000 TSO, J. YUN 1642 L. Helms				

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.¹	Document Number Number Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
······································	1			•			
***************************************	<u> </u>						
	·						
	·						
	·						
·····							
	ļ						
	<u> </u>						
				,			
			the state of the s				
			(T. Market (1912 http://doi.org/10.1016/10.1016/10.1016/10.1016/10.1016/10.1016/10.1016/10.1016/10.1016/10.1016			
	 						
	<u> </u>						
	l						

	FOREIGN PATENT DOCUMENTS										
Examiner Cit	1 Totalgitt datin Bedament Tublic				Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear							
					·						
	ļ							<u> </u>			
	 										
	ļ		***************************************		4						

Examiner	Date	
Signature	Considered	•
1 2	l l	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. 61011069

Substitute fo	or form 1449B/PTO			Complete if Known		
				Application Number	09/618,380	
INFO	RMATION DIS	CLOS	URE	Filing Date	July 18, 2000	
STAT	EMENT BY A	PPLIC	ANT	First Named Inventor	TSO, J. YUN	
				Art Unit	1642	
(Use as many sheets as n	ecessary)		Examiner Name	L. Helms	
Sheet	2	of	3	Attorney Docket Number	011823-004920US	

		NON PATENT LITERATURE DOCUMENTS					
xaminer nitials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	AA	ALEGRE et al., "Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a "Humanized" OKT3 Monoclonal Antibody," J. Immunology, 148(11):3461-3468 (1992).					
AB BURGERS et al.,"The challenges of HIV vaccine development and testing," Best Practice and Research Clinic Obstetrics and Gynaecology, 19:277-291 (2005).							
······································	AC	COLE et al., "HuM291, A Humanized Anti-CD3 Antibody, Is Immunosuppressive to T cells while Exhibiting Reduced Mitogenicity In Vitro," <u>Transplantation</u> , 68(4):563-571 (1999).					
AD CHATENOUD et al., "In-vivo anti-CD3 treatment of autoimmune patients," <u>Lancet</u> , 1(8655):164 (1989).							
	AE FANGER et al., "Bispecific antibodies for targeted cellular cytotoxicity," <u>Trends in Biotech.</u> , 9(11):375-380 (1991).						
AF HOLLIGER et al., "Engineering bispecific antibodies," <u>Curr. Opin. Biotech.</u> , 4(4):446-449 (1993). AG NOLAN et al., "Bifunctional antibodies: concept, production and applications," <u>Biochem. Biophys. Acta.</u> , 1040(1):1-11 (1990).							
						АН	OWENS et al., "Minireview, The genetic engineering of monoclonal antibodies," J. Immunol. Methods, 168(2):149-165 (1994).
•••••	ΑĬ	Wikipedia encyclopedia, 2006, "The Immune System, pages 1-12.					
	AJ	WINTER et al., "Humanized Antibodies," <u>Trends in Pharmacol. Sci.</u> , 14(5):139-143 (1993).					
	AK	WINTER et al., "Humanized antibodies," <u>Immunology Today</u> , 14(6):243-246 (1993).	Г				
. 1			· .				
aminer gnature		Date Considered					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
not considered. Include conv. of this form with next communication to applicant

not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	09/618,380	
INFORI	MATION D	ISCLOS	URE	Filing Date	July 18, 2000	
STATEMENT BY APPLICANT			ANT	First Named Inventor	TSO, J. YUN	
				Art Unit	1642	
(Use as many sheets as necessary)				Examiner Name	L. Helms	
Sheet	3	of	3	Attorney Docket Number	011823-004920US	

Examiner Signature	·	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.